A Nevada overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
30.8% of Nevada adults have obesity (CDC BRFSS, 2023; n=2,447, 95% CI 27.9–33.8) 4, and 66.4% are classified as overweight (35.6%) or living with obesity when the two categories are combined 5.
Nevada's population is 3,267,467 in the Census Bureau's Vintage 2024 estimates 6, up roughly 1.65% — about 53,100 residents — from 2023 to 2024 6.
Nevada Medicaid does not cover GLP-1 drugs (Ozempic, Trulicity, Rybelsus, Wegovy, Zepbound, etc.) for obesity or weight loss as a standalone indication. Per the Medicaid Services Manual (MSM) Chapter 1200, Appendix A, Section KK "Incretin Mimetics," routine coverage requires prior authorization and is limited to (1) type 2 diabetes glycemic control, or (2) cardiovascular-risk reduction in patients who already have type 2 diabetes and established cardiovascular disease — the manual states directly that medication "is not being prescribed for weight loss in absence of T2DM indication" 1.
Two narrow non-diabetic exceptions exist and neither treats obesity itself. Wegovy is covered only for reducing major adverse cardiovascular events in non-diabetic adults with established cardiovascular disease and BMI ≥27, prescribed by or with a cardiologist/vascular specialist. Zepbound is covered only for moderate-to-severe obstructive sleep apnea in non-diabetic adults with BMI >30, prescribed by or with a sleep specialist/pulmonologist. Saxenda, Qsymia, Contrave, phentermine, and orlistat appear nowhere in the chapter and are not covered in any form 1.
This is dated policy language: the MSM revision is effective August 3, 2026 (MTL 23/26), with Section KK pp.136–140 and Section 1203.1(F) p.7 carrying the criteria. Page-date note: p.136 (section header plus base T2DM-only criteria) is stamped April 6, 2026; pp.137–140 (full Wegovy CV/BMI and Zepbound OSA criteria, including recertification) are stamped January 5, 2026, and Section KK was not among the sections the August 3, 2026 transmittal changed 12. KFF's January 2026 issue brief corroborates the picture but is not the primary source 3.
Astra's price in Nevada is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Nevada-specific price, surcharge, or discount.
This hub does not carry a local-clinic price table; verified Reno-area prices belong on the Reno page, with their own sources and checked dates.
About 11.35% of Nevadans were uninsured in 2024. That figure was computed by summing all 'no health insurance coverage' age/sex cells in ACS Table B27001 (2024 1-year estimate) and dividing by the table's universe total; it is not a single pre-tabulated ACS figure, was verified once by script, and has not been cross-checked against a published KFF or Census QuickFacts rate 8. Median household income is $78,260 (ACS 2020–2024 5-year estimate) 7.
In a state that added roughly 53,100 residents in a single year 6, specialist supply outside the Reno and Las Vegas metros does not keep pace with population — which is exactly the barrier a video visit removes, statewide.
Telehealth prescribing authority in Nevada runs through the Nevada State Board of Medical Examiners (medboard.nv.gov) 9. We are verifying Nevada's specific telehealth rules — check back. No specific Nevada rule text is asserted on this page until that verification is complete.
Astra is licensed in all 50 states, Nevada included — all of Nevada, including rural counties outside Reno, is served by telehealth. The Reno page carries that city's verified local prices.
Astra treats patients in Nevada through state-licensed physicians.
Reno is currently Nevada's only city page; see the Reno breakdown for verified local clinic prices.
No. Nevada Medicaid's own Medicaid Services Manual (Chapter 1200, Appendix A, Section KK) limits routine coverage to type 2 diabetes and diabetes-related cardiovascular risk, and states directly that medication is not prescribed for weight loss absent a T2DM diagnosis. Two narrow exceptions exist — Wegovy for cardiovascular risk reduction in non-diabetic adults with existing heart disease and BMI ≥27, and Zepbound for moderate-to-severe sleep apnea in non-diabetic adults with BMI >30 — but obesity itself is never the covered diagnosis in either case.
The same as everywhere else Astra operates: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans billed annually ($816 and $1,416 respectively). Astra does not set a different price for Nevada or any other state.
Astra's price doesn't change by location, so whether it's 'cheaper in Nevada' depends entirely on what local providers charge. See the Reno city page for verified, dated local price comparisons with sources — this hub doesn't collect clinic-level pricing itself.
Yes. Astra is licensed in all 50 states, including every part of Nevada. Care is delivered by telehealth, so residents outside Reno — including rural counties — have the same access.
The Nevada State Board of Medical Examiners oversees physician licensing and prescribing rules in the state. Nevada-specific telehealth prescribing requirements are still being verified for this page — see the Board's site directly for current requirements in the meantime.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.